Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults: A Randomized Clinical Trial

JAMA Pediatr. 2021 Jun 1;175(6):631-632. doi: 10.1001/jamapediatrics.2020.6150.

Abstract

This randomized clinical trial examines the superiority of a single dose of rituximab vs low-dose mycophenolate mofetil in preventing the recurrence of steroid-dependent nephrotic syndrome in children and young adults.

Trial registration: ClinicalTrials.gov NCT04402580.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Drug Therapy, Combination
  • Enzyme Inhibitors / administration & dosage*
  • Female
  • Humans
  • Immunologic Factors / administration & dosage*
  • Italy
  • Male
  • Mycophenolic Acid / administration & dosage*
  • Nephrotic Syndrome / drug therapy*
  • Recurrence
  • Remission Induction
  • Risk
  • Rituximab / administration & dosage*
  • Steroids / administration & dosage
  • Young Adult

Substances

  • Enzyme Inhibitors
  • Immunologic Factors
  • Steroids
  • Rituximab
  • Mycophenolic Acid

Associated data

  • ClinicalTrials.gov/NCT04402580